ZD 9331

05/01/2003 - "This phase I dose-escalation trial investigated the tolerability, efficacy and pharmacokinetics of ZD9331 in Japanese patients with refractory, solid malignancies. "
05/01/2003 - "Phase I dose-escalation trial of ZD9331 in Japanese patients with refractory, solid malignancies."
04/01/2002 - "To assess the toxicity profile and dose-limiting toxicities (DLTs), to determine the maximum-tolerated dose, and to study the pharmacokinetics of ZD9331 when administered orally to patients with advanced solid tumors. "
09/01/2000 - "As of June 1998, ZD-9331 was in phase II trials for advanced colorectal and other solid tumors [315489], with drug filings not expected until 2002 [349551]. "
06/01/2003 - "Forty-five patients with refractory solid malignancies received ZD9331, which was escalated from 0.125 mg/m(2)/day. "

05/01/2003 - "ZD9331, as a first-line treatment for patients with advanced gastric cancer, demonstrated clinical activity and manageable toxicity."
05/01/2003 - "Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer."
05/01/2003 - "This phase II trial was designed to determine the antitumour activity and tolerability of ZD9331 given as a first-line therapy to patients with advanced gastric cancer. "
08/01/2005 - "These encouraging results warrant further preclinical investigations and clinical trials on the use of BGC9331 combined with SN-38/CPT-11 in treatment of patients with advanced colorectal or gastric cancers."

08/01/2004 - "This study investigated the efficacy and tolerability of ZD9331 as second- or third-line treatment for patients with advanced colorectal cancer (aCRC). "
02/01/2002 - "ZD9331, a highly specific TS inhibitor that dose not require polyglutamation for its activation, has shown activity in patients with refractory ovarian and colorectal cancer. "
08/01/2004 - "ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial."
12/01/2004 - "A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients."
12/01/2004 - "ZD9331 90 mg/m2 combined with CPT-11 180 mg/m2 may be a viable option for treatment of metastatic colorectal cancer, with possible escalation to 120 mg/m2 of ZD9331 according to safety evaluation."

11/01/2003 - "A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer."
11/01/2003 - "The preliminary evidence of efficacy and acceptable tolerability of ZD9331 in this heavily pretreated population with ovarian cancer warrants further investigation, especially in a less heavily pretreated patient population."
11/01/2003 - "This Phase II, multicenter, open-label study was conducted to assess the efficacy and tolerability of ZD9331, a novel direct-acting thymidylate synthase inhibitor, in heavily pretreated patients with ovarian cancer. "
05/01/2003 - "ZD9331, in combination with topotecan, showed manageable toxicity and some evidence of activity in patients with ovarian cancer."
04/01/2003 - "Pharmacodynamics of ZD9331 were determined by measurement of plasma deoxyuridine, which increased at all of the dose levels; dose-related increases in plasma deoxyuridine were significant (P = 0.003) on day 5. Stable disease was observed in 37% of patients; 23% of ovarian cancer patients had a > or =50% reduction in CA125 levels. "

05/01/2003 - "All three trials included an i.v. arm of ZD9331 at a dose of 130 mg/m2; the ovarian study also included a 65 mg/m2 i.v. treatment arm and the breast cancer trial included a 3 mg oral treatment arm. "
05/01/2003 - "ZD9331 has a manageable toxicity profile, and shows some evidence of activity in patients with relapsed or refractory NSCLC, ovarian and breast cancer."
08/01/2005 - "Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms."